INTRODUCTION
============

Hepatitis C virus (HCV) is a major leading cause of chronic liver disease including cirrhosis and hepatocellular carcinoma and about 130 to 150 million people globally have chronic hepatitis C (CHC) infection.[@b1-gnl-11-270],[@b2-gnl-11-270] According to the sequencing of HCV isolate, there are seven genotypes and 67 subtypes.[@b3-gnl-11-270] While genotype 1, 2, and 3 are more prevalent and found around the world-wide, genotype 4, 5 and 6 are distributed in limited area. Genotype 4 and 5 are mainly distributed in the Middle East and Africa, and 6 in the Southern China and Southeast Asia including Singapore, Laos, Thailand, Vietnam, and Myanmar, where comprises up to 50% of all hepatitis C patients. On the other hand, HCV genotype 6 is rare in Korea where its prevalence is known as about 1%.[@b4-gnl-11-270],[@b5-gnl-11-270]

Since new oral direct-acting-agents (DAA) have been introduced, a treatment paradigm for HCV infection is changing. However, although some clinical trials demonstrated higher sustained virologic response (SVR) achievement in genotype 6 patients using DAA, those data included only small number of patients with genotype 6.[@b6-gnl-11-270],[@b7-gnl-11-270] Moreover, DAA-based regimen is not likely to be available in many countries yet because of countries' or personal socio-economic situations. For these reasons, peginterferon (PEG-IFN) and ribavirin are still affordable treatment regimens in real-world setting.

This study was conducted to find the clinical characteristics and treatment outcomes in the patients infected with HCV genotype 6 in Korea.

MATERIALS AND METHODS
=====================

From April 2004 to December 2014, data of patients infected with genotype 6 were reviewed from one regional hospital and seven hospitals affiliated with medical colleges located in Gyeonggi-Incheon region, South Korea. Among them, seven patients were from the Gyeonggi-Incheon Peginterferon Alpha and Ribavirin Effect in CHC Treatment (KIPECT) study group.[@b8-gnl-11-270]

Baseline clinical and virologic characteristics were obtained by retrospective review of medical records. Data collection was performed with an Excel (Microsoft Corp., Redmond, WA, USA)-based case report form by physicians at each individual hospital. The study protocol was approved by the Institutional Review Boards for exemption from the requirement for informed consent at each hospital and was conducted in accordance with the principles of the Declaration of Helsinki.

All patients were Koreans and anti-HCV positive more than 6 months or clinically assessed as a CHC by using laboratory and radiologic findings. HCV genotyping was conducted by the reverse hybridization principle, nested polymerase chain reaction (PCR) was performed with biotinylated primers from the 5′ untranslated region, and the second-round product was genotyped with a second-generation line probe assay (INNO-LiPA HCV II; Innogenetics, Ghent, Belgium) or restriction fragment mass polymorphism (RFMP; Genematrix Inc., Seongnam, Korea), or direct sequencing method as used in each institution. Qualitative HCV RNA, when it performed, was conducted by an RNA PCR and hybrid method, Cobas Amplicor HCV test version 2.0 (Roche Molecular Systems, Branchburg, NJ, USA; detection limit, 50 IU/mL). Quantitative HCV RNA was measured by real-time PCR assay using the Abbott RealTime HCV assay (Abbott Molecular, Des Plaines, IL, USA; lower detection limit 12 IU/mL) or CobasAmpliPrep/CobasTaqMan HCV assay (Roche Molecular Systems, Pleasanton, CA, USA; lower detection limit 15 IU/mL).

When the patients were treated, either PEG-IFN α-2a or PEG-IFN α-2b plus ribavirin were used. The starting dosage and dose modification of PEG-IFN and ribavirin were determined based on the current guidelines suggested by the Korean Association for the Study of the Liver. However, according to the nature of this retrospective study, selection and discontinuation as well as dosing and treatment duration of PEG-IFN and ribavirin were not controlled, but reflected the clinical practice of the attending physicians.

The patients who developed anemia, neutropenia, and/or thrombocytopenia were generally managed with a dose reduction or permanent discontinuation of the PEG-IFN or ribavirin, as per the guidelines provided.

A rapid virological response (RVR) was defined as undetectable serum HCV-RNA at week 4. The complete early virologic response (cEVR) is based on week 12 data and is defined as an undetectable HCV RNA. A partial EVR (pEVR) refers to a 2 log~10~ or greater decrease from baseline in HCV RNA at week 12, but persistent detectable HCV RNA. End of treatment response (ETR) was defined as undetectable HCV RNA at the end point of treatment. A SVR was defined as undetectable HCV RNA 24 weeks after completion of antiviral therapy maintained throughout the remaining documented follow-up period. Virological relapse was defined as achieving an ETR but subsequently becoming HCV RNA positive after cessation of treatment. An adherence to antiviral therapy was defined as the actual dose administered divided by the total dose first expected.

Comparison of treatment outcome according to the presence of RVR and the treatment duration was performed using two-sided Fisher exact test.

RESULTS
=======

A total of 32 patients were enrolled. Included patients were aged between 34 and 57 (median, 44) years, and 63% were male. No specific risk for CHC was identified but two patients who received tattooing from the same unlicensed person. Three patients showed hepatitis B surface antigen (HBsAg) positive but negative HBV DNA on their serum ([Table 1](#t1-gnl-11-270){ref-type="table"}).

Most common subtype was 6c, documented in 26 patients (81%). There were 6a in three patients, mixed 6/6c in two patients, and 6 in one patient, respectively. Baseline median aspartate transaminase level was 80 (24 to 1,123) U/L and alanine transaminase level was 88 (21 to 1,019) U/L, and HCV RNA level was 1,405,000 (96,500 to 28,844,529) IU/mL. Based on laboratory and imaging findings, five patients showed clinical features suggestive liver fibrosis.

Twenty-five treatment-naïve patients were treated with 180 μg of PEG-IFN α-2a or 1.0 to 1.5 μg/kg of PEG-IFN α-2b with 800 to 1,200 mg of ribavirin. Treatment duration was determined by physicians' discretion, and intended treatment duration was ranged 24 to 54 weeks ([Table 2](#t2-gnl-11-270){ref-type="table"}).

Overall, SVR was attained in 13 patients (52%). As follow-up loss occurred in three patients, a total of 22 patients conformed to the treatment protocol. Seven patients relapsed and two were null-responders including one who discontinued treatment for no early virologic response.

By treatment durations, four of 10 patients attained SVR following 24 weeks and nine of 12 patients following more than 48 weeks treatment. When excluding three patients who lost follow-up, the treatment outcome was slightly improved according to longer duration of treatment (p=0.192).

RVR was checked in 14 patients. Five of six patients who showed positive RVR had attained SVR whereas four of eight patients without RVR attained SVR. Two patients who did not achieve EVR were nonresponder. In three patients with pEVR, two were relapsed and one attained SVR (p=0.301).

Most common adverse event was flu-like syndrome, and dose reduction was necessary in 24% (6/25) of patients. There was no treatment discontinuation by adverse events.

DISCUSSION
==========

HCV genotype 6 is geographically restricted in South East Asia and surrounding regions, where 30% to 50% of all hepatitis C patients are infected with genotype 6.[@b9-gnl-11-270]--[@b11-gnl-11-270] Diverse subtypes of genotype 6 are accumulated and newly isolated subtypes are almost always reported in this area. So, it is suggested that genotype 6 may have been long circulated or evolved within Southeast Asia, and transmitted to the adjacent countries.[@b12-gnl-11-270] Whereas most data about genotype 6 HCV were centered on these regions, there have been not many data in Korea probably due to low prevalence of HCV genotype 6. While Shin *et al*.[@b13-gnl-11-270] recently reported the prevalence of genotype 6 as 10.5%, most other studies reported the prevalence as about 1.0%.[@b8-gnl-11-270],[@b13-gnl-11-270]--[@b15-gnl-11-270] The affiliated hospital of Shin *et al*.[@b13-gnl-11-270] is located where many immigrants from Southeast Asia and China and drug abusers exist, which may explain the higher prevalence than others.

Genotype 6 HCV is highly diverse with 23 subtypes and certain subtypes have different geographic predominance like genotypes; 6a in South China, Taiwan, and Hong Kong, 6n in Myanmar, 6f in Thailand, and 6g in Indodesia.[@b1-gnl-11-270],[@b16-gnl-11-270] Until recently, subtype 6c is an overwhelming subtype regardless of genotyping methods in Korea.[@b13-gnl-11-270]--[@b15-gnl-11-270] Interestingly, clustered 6c has not been reported but in Korea since first isolated as a sole strain from a commercial blood donor in Thailand.[@b17-gnl-11-270] We assume that 6c is a rare HCV variant and its spread within Korea might be related with migration of some hosts.

In this study, RFMP was most commonly used, that is known as accurate for HCV genotyping. On the other hand, INNO-LiPA HCV II (Innogenetics) has been criticized due to less complete ability to distinguish genotype 6 from 1, especially 6a from 1b.[@b15-gnl-11-270],[@b18-gnl-11-270]--[@b21-gnl-11-270] Although a gold standard for genotyping and subtyping is direct sequencing assay, RFMP assay could distinguish mass differences between oligonucleotide fragment levels and be most reliable modality among commercial kits. We also suggest that further study is required to investigate the prevalence and distribution of each subtypes of genotype 6 with direct sequencing or combining two or more modalities.

To date, virological and clinical features of hepatitis C genotype 6 are known to be not significantly different to genotype 1, and 2/3.[@b1-gnl-11-270],[@b16-gnl-11-270],[@b22-gnl-11-270] However, Korean patients infected with genotype 6 tend to be younger and have chronic hepatitis rather than advanced stage such as hepatocellular carcinoma or cirrhosis.[@b11-gnl-11-270],[@b23-gnl-11-270] These suggest that it has been not so long since a transmission into Korea and propagation of HCV genotype 6 occurred. We would prevent further amplification of genotype 6 infection in Korea by tracking human migration and transmission route of genotype 6 HCV.

Genotype is an important factor of response to treatment. Prior studies have suggested that the HCV genotype 6 has responded to the IFN-based treatment better than genotype 1 but less than genotype 2/3. The 48-week treatment may be more effective to achieve SVR than 24-week treatment in PEG-IFN and ribavirin combination. Those who achieve RVR may receive the shorter 24-week treatment.[@b23-gnl-11-270]--[@b27-gnl-11-270] Despite statistically insignificant with too small sample size, our results showed a similar trend to the prior data. In our study, SVR rates were 40% and 75% according to the 24- and more than 48-week of PEG-IFN and ribavirin treatment respectively and RVR showed high positive predictive value (83%).

Since the introduction of DAA, a treatment paradigm for CHC has been rapidly changing. Combination of PEG-IFN and ribavirin is not recommended as a standard treatment of genotype 1 anymore and plays a minimal role even in genotype 2/3.[@b5-gnl-11-270],[@b28-gnl-11-270],[@b29-gnl-11-270] However, unlike the major genotypes of HCV infection, data about minor genotypes such as genotype 6 are still limited.[@b6-gnl-11-270],[@b30-gnl-11-270] In addition, a surpassing cost per SVR of DAA is a major hurdle in the real world.[@b31-gnl-11-270],[@b32-gnl-11-270] Considering that a compulsory public health care system exists in Korea, where the lowest cost per cure is a more valuable, PEG-IFN and ribavirin could not be discarded yet. Therefore, we consider the results of our study are still meaningful for guide to treat patients infected with genotype 6 HCV.

This is a retrospective study. Nevertheless, a prospective study about genotype 6 HCV is hardly to be established due to low prevalence. To overcome inhomogeneity of enrolled patients and treatment regimen, the subjects were limited as Koreans.

In this study, we showed that Korean patients infected genotype 6 HCV tended to be younger and have relatively short infection duration comparing to those who in the prevalent area. In Korea, 6c is the most common subtype. When treated with PEG-IFN and ribavirin combination, the overall SVR rate was observed as 52% (13/25) in patients. As like other HCV infection, longer duration of treatment and attainment of RVR are favorable to achieve SVR in genotype 6 HCV infection. Although the treatment profile of our study is not an updated one, we believe that this is valuable data to have insights regarding the evolution and spread of genotype 6 HCV in Korea and manage patients infected with genotype 6 HCV.
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###### 

Clinical Characteristics of Patients with Chronic Hepatitis C Genotype 6

  No.   Sex/age   Genotyping method   Subtype   Baseline HCV RNA, IU/mL   AST, U/L   ALT, U/L   WBC, /μL   Hb, g/dL   Platelets, ×10^3^/μL   Alcohol[\*](#tfn2-gnl-11-270){ref-type="table-fn"}, g/day   Remark     US
  ----- --------- ------------------- --------- ------------------------- ---------- ---------- ---------- ---------- ---------------------- ----------------------------------------------------------- ---------- -----
  1     M/45      INNO-LiPA           6a        3,948,730                 57         67         5,780      16.5       167                    10                                                          \-         \-
  2     M/53      INNO-LiPA           6c        Positive                  122        28         5,430      14.0       54                     Nil                                                         \-         \-
  3     M/46      RFMP                6a        1,670,000                 121        181        4,350      15.7       124                    Nil                                                         \-         \-
  4     F/39      RFMP                6a        185,040                   46         108        5,720      16.0       126                    60                                                          \-         \-
  5     M/54      RFMP                6c        283,400                   97         78         3,260      14.0       156                    Nil                                                         Diabetes   \-
  6     M/37      RFMP                6c        7,560,000                 78         154        5,840      15.9       224                    25                                                          \-         \-
  7     M/35      RFMP                6c        5,170,000                 224        236        4,970      15.6       95                     25                                                          Diabetes   CLD
  8     M/45      RFMP                6c        789,285                   71         117        7,400      15.2       110                    Nil                                                         \-         \-
  9     M/36      RFMP                6c        28,844,529                55         85         5,900      15.0       201                    Nil                                                         \-         \-
  10    M/48      RFMP                6c        356,089                   87         47         3,900      16.4       33                     10                                                          Diabetes   LC
  11    F/45      RFMP                6c        Positive                  72         91         6,900      13.1       195                    Nil                                                         \-         CLD
  12    F/50      Direct sequencing   6c        10,266,000                25         33         6,000      13.2       247                    Nil                                                         \-         \-
  13    F/40      RFMP                6c        1,260,000                 157        189        6,000      14.9       186                    Nil                                                         \-         CLD
  14    M/40      RFMP                6         1,650,000                 38         56         5,100      15.6       147                    Nil                                                         \-         \-
  15    M/41      RFMP                6c        9,330,000                 43         21         7,300      16.8       162                    30                                                          HBsAg+     \-
  16    F/39      RFMP                6a/c      1,127,568                 127        46         4,360      12.3       132                    Nil                                                         \-         \-
  17    F/36      RFMP                6c        13,068,693                50         71         4,790      13.8       174                    60                                                          \-         \-
  18    M/43      RFMP                6c        1,260,000                 157        189        5,500      14.9       186                    Nil                                                         Diabetes   \-
  19    F/43      RFMP                6/6c      4,980,000                 96         140        5,700      15.7       238                    Nil                                                         HBsAg+     \-
  20    M/54      Direct sequencing   6c        131,000                   183        373        4,200      13.7       176                    Nil                                                         \-         \-
  21    M/47      RFMP                6c        9,040,000                 34         63         5,800      14.3       279                    Nil                                                         \-         \-
  22    F/56      RFMP                6c        1,390,000                 88         136        5,300      13.1       165                    Nil                                                         \-         \-
  23    F/57      RFMP                6c        459,000                   45         29         3,600      13.2       155                    Nil                                                         \-         \-
  24    M/44      RFMP                6c        2,720,000                 102        190        5,200      15.1       177                    20                                                          \-         \-
  25    M/49      RFMP                6c        975,000                   100        64         4,700      15.2       54                     Nil                                                         \-         LC
  26    M/49      RFMP                6c        96,500                    151        479        5,300      16.9       233                    Nil                                                         \-         \-
  27    M/40      RFMP                6c        1,420,000                 56         67         8,400      16.4       136                    10                                                          HBsAg+     \-
  28    M/50      RFMP                6c        637,000                   82         173        5,800      15.7       122                    Nil                                                         \-         \-
  29    M/34      RFMP                6c        1,270,000                 139        350        4,900      16.9       243                    20                                                          \-         \-
  30    F/38      RFMP                6c        7,000,000                 54         33         5,500      13.5       191                    Nil                                                         \-         \-
  31    M/37      RFMP                6c        609,300                   1,123      1,019      4,560      16.1       103                    40                                                          \-         \-
  32    F/39      RFMP                6c        9,106,107                 24         24         5,640      13.1       178                    Nil                                                         \-         \-

HCV, hepatitis C virus; AST, aspartate transferase; ALT, alanine transferase; WBC, white blood cell; Hb, hemoglobin; US, ultrasonography; M, male; INNO-LiPA, line probe assay; RFMP, restriction fragment mass polymorphism; F, female; CLD, chronic liver disease; LC, liver cirrhosis; HB-sAg+, hepatitis B surface antigen positive.

Estimated amount.

###### 

Treatment Profile of Patients with Genotype 6 Who Received Peginterferon and Ribavirin

  No.   PEG-IFN   Initial ribavirin dose, mg   PEG-IFN adherence, %   Ribavirin adherence, %   Intended treatment duration   RVR   EVR    ETR   SVR
  ----- --------- ---------------------------- ---------------------- ------------------------ ----------------------------- ----- ------ ----- --------------
  1     2a        800                          100                    100                      24                            \-    cEVR   Yes   Relapse
  2     2a        600                          100                    100                      24                            No    No     \-    Nonresponder
  3     2a        1,000                        100                    100                      48                            \-    pEVR   Yes   Relapse
  4     2a        1,000                        100                    100                      48                            Yes   cEVR   Yes   Yes
  5     2a        1,000                        79                     83                       48                            Yes   cEVR   Yes   Yes
  6     2a        1,000                        93                     95                       48                            \-    pEVR   Yes   Yes
  8     2a        900                          100                    100                      24                            \-    cEVR   Yes   Yes
  9     2b        1,200                        100                    100                      48                            No    No     No    Nonresponder
  10    2b        800                          100                    100                      24                            \-    cEVR   Yes   Relapse
  11    2b        1,000                        100                    100                      24                            \-    cEVR   Yes   Relapse
  12    2a        1,000                        100                    100                      24                            No    pEVR   Yes   Relapse
  13    2a        1,000                        100                    100                      16                            \-    cEVR   \-    F/U loss
  14    2a        1,000                        100                    100                      13                            \-    cEVR   \-    F/U loss
  15    2b        1,000                        100                    100                      48                            No    cEVR   Yes   Yes
  16    2b        1,000                        84                     82                       54                            Yes   cEVR   Yes   Yes
  17    2a        800                          98                     100                      48                            No    cEVR   Yes   Yes
  18    2a        1,000                        100                    82                       48                            \-    cEVR   Yes   Yes
  19    2a        1,000                        100                    100                      48                            \-    cEVR   Yes   Yes
  20    2a        1,000                        100                    100                      24                            Yes   cEVR   Yes   Yes
  21    2b        800                          100                    100                      24                            No    cEVR   Yes   Yes
  22    2b        800                          100                    100                      48                            \-    cEVR   Yes   Relapse
  23    2b        800                          100                    75                       24                            Yes   cEVR   Yes   Relapse
  28    2b        1,000                        100                    100                      24                            No    cEVR   Yes   Yes
  29    2b        1,000                        100                    100                      48                            Yes   cEVR   Yes   Yes
  32    2b        800                          100                    100                      20                            No    cEVR   \-    F/U loss

PEG-IFN, peginterferon; RVR, rapid virologic response; EVR, early virologic response; ETR, end of treatment response; SVR, sustained virologic response; cEVR, complete early virologic response; pEVR, partial early virologic response; F/U, follow up.
